Entries by Dana Fowlkes

September 25, 2018:

FORGE Life Science is awarded its first Department of Defense STTR contract (W911QY18P0300) from the Joint Project Manager Medical Countermeasure Systems. Proposal titled, “Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum Medical Countermeasure Against Marburg Virus”.

September 4, 2018:

FORGE Life Science CEO, Lillian Chiang, presents at the National Institutes of Health CMV Workshop, Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment.

August 29, 2018:

The European Patent Office grants patent EP 2670404 B1, allowing claims directed to antiviral treatments with inhibitors of two or more sirtuins. This I.P. is exclusively licensed by FORGE from Princeton University. Read more

August 20, 2018:

FORGE Life Science CEO, Lillian Chiang, presents at the Military Health System Research Symposium, Kissimmee, FL. Read more

August 14, 2018:

Life Science completes its Phase I milestones and receives a Notice of Award for the Phase II component of its FastTrack SBIR grant titled, “Sirtuin Agonists as Pan Influenza Antivirals” (4R44AI122488-02). Read more

July 15, 2018:

FORGE Life Science enters into a Sponsored Research Agreement with St. Jude Children’s Research Hospital. FORGE will collaborate with Drs. Richard J. Webby and Elena Govorkova to study the effect of FORGE host-targeted antivirals in ferret models of respiratory infection.

June 18, 2018:

FORGE Life Science enters into a Cooperative Research & Development Agreement with the U.S. Army Medical Research Institute of Infectious Disease to test FORGE host-targeted antivirals against Department of Defense priority pathogens such as Marburg virus, Venezuelan equine encephalitis virus, and Lassa virus.

April 25, 2018:

FORGE Life Science President & CEO, Lillian Chiang, is selected to join Springboard Enterprises Health Innovation Hub 2018: Life Sciences Track cohort for women entrepreneurs. Read more

February 28, 2018:

FORGE Life Science completes Milestone 1 in agreement with BioArdis, LLC, securing second tranche of in-kind services investment.

December 1, 2017:

FORGE Life Science announces final close of $6.3 M raised in Series A-1 financing with participation by all founding investors. The funds will progress FORGE’s novel first-in-class host-targeted antivirals towards delivering transformational broad-spectrum treatment modalities to patients in need.